Runben Biotechnology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	1,517	1,317	1,032	855.65	581.91	442.66
Other Revenue	0.77	0.77	0.66	0.44	0.24	0.17
Revenue	1,518	1,318	1,033	856.09	582.15	442.83
Revenue Growth (YoY)	21.75%	27.61%	20.66%	47.06%	31.46%	58.93%
Cost of Revenue	637.28	553.2	453.34	393.28	275.75	210.99
Gross Profit	880.9	764.98	579.62	462.81	306.4	231.83
Selling, General & Admin	502.36	411.86	301.68	257.21	155.39	109.8
Research & Development	35.59	35.07	25.69	19.51	13.6	10.71
Other Operating Expenses	10.11	9.39	9.42	8.77	6.83	4.46
Operating Expenses	548.91	456.79	336.99	285.47	175.82	125
Operating Income	331.99	308.19	242.62	177.34	130.58	106.84
Interest Expense	-0.09	-0.13	-0.26	-0.43	-0.54	-
Interest & Investment Income	24.72	34.84	16.4	7.18	6.09	0.8
Currency Exchange Gain (Loss)	-	-	-	-	0.24	-
Other Non Operating Income (Expenses)	-5.29	-0.13	-0.05	-0.16	-0.05	-0.03
EBT Excluding Unusual Items	351.33	342.76	258.72	183.94	136.32	107.61
Gain (Loss) on Sale of Investments	3.99	3.59	-	-	-	0.36
Gain (Loss) on Sale of Assets	-0.28	-0.6	0.07	0.05	0	-
Asset Writedown	0.74	-	-	-	-	-
Other Unusual Items	6.25	6.25	9.13	4.29	5.31	2.28
Pretax Income	362.03	352	267.93	188.27	141.63	110.24
Income Tax Expense	56.71	51.84	41.9	28.23	20.98	15.53
Net Income	305.33	300.16	226.03	160.04	120.65	94.71
Net Income to Common	305.33	300.16	226.03	160.04	120.65	94.71
Net Income Growth	-0.28%	32.80%	41.23%	32.66%	27.38%	165.51%
Shares Outstanding (Basic)	402	406	353	341	335	306
Shares Outstanding (Diluted)	402	406	353	341	335	306
Shares Change (YoY)	-0.22%	14.85%	3.71%	1.61%	9.69%	499.54%
EPS (Basic)	0.76	0.74	0.64	0.47	0.36	0.31
EPS (Diluted)	0.76	0.74	0.64	0.47	0.36	0.31
EPS Growth	-0.05%	15.63%	36.17%	30.56%	16.13%	-55.71%
Free Cash Flow	194.68	183.02	238.87	124.67	-13.38	28.93
Free Cash Flow Per Share	0.48	0.45	0.68	0.37	-0.04	0.10
Dividend Per Share	0.430	0.410	0.170	-	-	-
Dividend Growth	22.86%	141.18%	-	-	-	-
Gross Margin	58.02%	58.03%	56.11%	54.06%	52.63%	52.35%
Operating Margin	21.87%	23.38%	23.49%	20.71%	22.43%	24.13%
Profit Margin	20.11%	22.77%	21.88%	18.70%	20.72%	21.39%
Free Cash Flow Margin	12.82%	13.88%	23.13%	14.56%	-2.30%	6.53%
EBITDA	351.44	327.81	262.46	194.59	138.59	114.84
EBITDA Margin	23.15%	24.87%	25.41%	22.73%	23.81%	25.93%
D&A For EBITDA	19.46	19.62	19.84	17.25	8.01	8.01
EBIT	331.99	308.19	242.62	177.34	130.58	106.84
EBIT Margin	21.87%	23.38%	23.49%	20.71%	22.43%	24.13%
Effective Tax Rate	15.66%	14.73%	15.64%	14.99%	14.82%	14.09%
Revenue as Reported	1,518	1,318	1,033	856.09	582.15	442.83
Advertising Expenses	-	320.61	218.47	187.47	107.9	77.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.